04:57 AM EDT, 06/11/2025 (MT Newswires) -- MaxCyte ( MXCT ) and Ori Biotech said Wednesday they are collaborating to improve efficiency, scalability, and productivity in cell therapy manufacturing.

The collaboration will specifically assess how Ori Biotech's IRO platform can optimize the yield and streamline the manufacturing timelines of MaxCyte ( MXCT )-engineered primary T cells, compared with traditional post-electroporation cell expansion processes, the companies said.

The partners have selected CD19 CAR expression via CRISPR knock-in in activated T cells as the test system for initial assessment, they said.